
  
    
      
        Introduction_NNP
        Steroid_NNP hormone_NN receptors_NNS (_( SHRs_NNP )_) are_VBP members_NNS of_IN a_DT family_NN
        of_IN ligand-activated_JJ transcription_NN factors_NNS that_WDT regulate_VB
        many_JJ biological_JJ processes_NNS ,_, including_VBG metabolism_NN ,_,
        reproduction_NN ,_, and_CC development_NN ._. In_IN the_DT absence_NN of_IN ligand_NN
        such_JJ as_IN androgen_NN ,_, glucocorticoid_NN ,_, progestin_NN ,_, and_CC
        mineralocorticoid_NN ,_, the_DT SHR_NNP maintains_VBZ a_DT cytosolic_JJ inactive_JJ
        state_NN by_IN association_NN with_IN heat_NN shock_NN proteins_NNS and_CC /_NN or_CC other_JJ
        proteins_NNS such_JJ as_IN corepressors_NNS ._. Upon_IN ligand_NN binding_VBG ,_, the_DT SHR_NNP
        undergoes_NNS conformational_NN changes_NNS that_WDT involve_VBP releas_NNS e_SYM from_IN
        the_DT repressor_NN proteins_NNS ,_, and_CC translocation_NN to_TO the_DT nucleus_NN
        where_WRB it_PRP can_MD bind_NN to_TO specific_JJ hormone_NN responsive_JJ sequences_NNS
        in_IN the_DT DNA_NNP of_IN genes_NNS regulated_VBN by_IN steroid_NN hormones_NNS [_NN 1_CD 2_CD ]_NN ._.
        The_DT mechanism_NN by_IN which_WDT SHRs_NNP affect_VB the_DT rate_NN of_IN RNA_NNP
        polymerase_NN II-directed_NNP transcription_NN likely_JJ involves_VBZ the_DT
        interaction_NN of_IN receptors_NNS with_IN components_NNS of_IN the_DT
        transcription_NN preinitialization_NN complex_JJ ._. This_DT interaction_NN
        may_MD be_VB direct_JJ ,_, or_CC it_PRP may_MD occur_VB indirectly_RB through_IN the_DT
        action_NN of_IN coactivators_NNS ,_, which_WDT act_VBP as_IN bridging_VBG factors_NNS ._. To_TO
        date_NN ,_, numerous_JJ coactivator_NN molecules_NNS have_VBP been_VBN isolated_VBN and_CC
        characterized_VBN ,_, encompassing_VBG several_JJ different_JJ families_NNS [_NN 3_CD
        4_CD ]_NN ._. Most_JJS of_IN these_DT cofactors_NNS are_VBP expressed_VBN in_IN a_DT wide_JJ
        variety_NN of_IN cell_NN types_NNS and_CC can_MD interact_NN with_IN more_JJR than_IN one_CD
        type_NN of_IN nuclear_JJ receptor_NN ._. The_DT recent_JJ findings_NNS that_IN members_NNS
        of_IN the_DT several_JJ different_JJ families_NNS of_IN coactivators_NNS possess_VBP
        intrinsic_JJ histone_NN acetyltransferase_NN activity_NN suggests_VBZ that_WDT
        activated_VBN SHRs_NNP ,_, and_CC nuclear_JJ receptors_NNS in_IN general_JJ ,_, may_MD also_RB
        recruit_VB these_DT cofactors_NNS to_TO remodel_NN chromatin_NN structure_NN for_IN
        better_JJR accessibility_NN of_IN the_DT transcriptional_NN machinery_NN to_TO
        DNA_NNP [_NN 5_CD 6_CD ]_NN ._.
        The_DT JAK_NNP /_NN STAT_NNP signaling_VBG pathway_NN is_VBZ involved_VBN in_IN many_JJ
        cytokines_NNS ,_, hormones_NNS ,_, and_CC growth_NN factors_NNS mediated_JJ signaling_VBG
        pathways_NNS to_TO regulate_VB a_DT variety_NN of_IN biological_JJ responses_NNS ,_,
        including_VBG development_NN ,_, cell_NN differentiation_NN ,_, proliferation_NN
        and_CC survival_NN [_NN 7_CD 8_CD ]_NN ._. Once_RB STAT_NNP proteins_NNS are_VBP activated_VBN by_IN
        tyrosine-phosphorylation_JJ ,_, form_NN homo_NN or_CC heterodimers_NNS that_WDT
        are_VBP translocated_JJ to_TO the_DT nucleus_NN ,_, where_WRB they_PRP can_MD bind_NN to_TO
        specific_JJ sequences_NNS in_IN the_DT DNA_NNP ,_, thereby_RB stimulating_VBG gene_NN
        transcription_NN ._. Similarly_RB to_TO nuclear_JJ receptors_NNS and_CC to_TO other_JJ
        transcription_NN factors_NNS ,_, STAT_NNP proteins_NNS can_MD interact_NN with_IN
        coactivators_NNS to_TO modulate_VBP their_PRP$ transcriptional_NN activity_NN [_NN 9_CD
        10_CD 11_CD 12_CD ]_NN ._. Other_JJ reports_NNS have_VBP shown_VBN direct_JJ interactions_NNS
        between_IN several_JJ members_NNS of_IN the_DT JAK_NNP /_NN STAT_NNP signaling_VBG pathway_NN
        with_IN SHRs_NNP [_NN 13_CD 14_CD 15_CD 16_CD ]_NN ._. Stat_NNP 3_CD is_VBZ one_CD of_IN the_DT seven_CD
        members_NNS of_IN the_DT STAT_NNP family_NN of_IN proteins_NNS that_WDT has_VBZ been_VBN shown_VBN
        to_TO modulate_VBP the_DT expression_NN of_IN several_JJ genes_NNS related_VBN to_TO
        control_VB cell_NN cycle_NN ,_, proliferation_NN and_CC apoptosis_NNS ,_, such_JJ as_IN
        Cyclin_NNP D_NNP 1_CD ,_, c-myc_JJ ,_, and_CC Bcl-x_NNP L_NNP ,_, respectively_RB [_NN 17_CD ]_NN ._.
        Accordingly_RB ,_, alterations_NNS in_IN the_DT activity_NN of_IN STAT_NNP 3_CD have_VBP been_VBN
        associated_VBN with_IN cell_NN transformation_NN and_CC cancer_NN progression_NN
        [_NN 18_CD 19_CD 20_CD ]_NN ._.
        Prostate_NNP cancer_NN is_VBZ the_DT most_RBS commonly_RB diagnosed_VBN cancer_NN ,_,
        and_CC the_DT second_JJ leading_VBG cause_NN of_IN death_NN from_IN cancer_NN in_IN North_JJ
        American_JJ men_NNS ._. Prostate_NNP cells_NNS are_VBP dependant_NN on_IN androgen_NN to_TO
        keep_VB their_PRP$ normal_JJ functions_NNS ._. Activation_NNP of_IN androgen_NN
        receptor_NN (_( AR_NNP )_) in_IN prostate_NN cells_NNS is_VBZ a_DT key_JJ step_NN in_IN developing_VBG
        and_CC progression_NN of_IN prostate_NN cancer_NN ._. Most_JJS patients_NNS respond_VBP
        initially_RB to_TO androgen_NN deprivation_NN or_CC antiandrogen_NN
        regiments_NNS ,_, but_CC eventually_RB the_DT tumor_NN relapses_NNS in_IN an_DT
        androgen-independent_JJ stage_NN with_IN a_DT poor_JJ outcome_NN ._. Several_JJ
        possible_JJ mechanisms_NNS have_VBP been_VBN suggested_VBN to_TO explain_VB this_DT
        activation_NN of_IN AR_NNP ,_, including_VBG mutations_NNS in_IN the_DT gene_NN encoding_VBG
        AR_NNP that_WDT alter_VBP the_DT specificity_NN for_IN androgens_NNS ,_, overexpression_NN
        of_IN the_DT AR_NNP protein_NN itself_PRP ,_, cross-talk_JJ to_TO other_JJ signal_NN
        transduction_NN pathways_NNS ,_, and_CC altered_VBD levels_NNS or_CC activity_NN of_IN
        coactivators_NNS [_NN 21_CD 22_CD 23_CD ]_NN ._. Several_JJ groups_NNS including_VBG ours_PRP
        have_VBP demonstrated_VBN a_DT role_NN of_IN activated_VBN Stat_NNP 3_CD in_IN the_DT
        proliferation_NN and_CC survival_NN of_IN prostate_NN cancer_NN cells_NNS by_IN a_DT
        mechanism_NN that_WDT involves_VBZ the_DT AR_NNP [_NN 24_CD 25_CD 26_CD 27_CD 28_CD ]_NN ._.
        In_IN this_DT study_NN ,_, we_PRP examined_VBD how_WRB Stat_NNP 3_CD activates_NNS the_DT SHRs_NNP
        including_VBG AR_NNP ._. We_PRP studied_VBD whether_IN Stat_NNP 3_CD ,_, a_DT transcription_NN
        factor_NN itself_PRP ,_, could_MD act_VB as_IN a_DT coactivator_NN for_IN AR_NNP and_CC for_IN
        other_JJ SHRs_NNP ._. We_PRP report_VBP here_RB that_IN a_DT constitutively_RB active_JJ
        form_NN of_IN Stat_NNP 3_CD stimulates_NNS transcriptional_NN activity_NN of_IN SHRs_NNP
        in_IN a_DT hormone-dependent_JJ manner_NN ._. We_PRP also_RB report_VBP that_IN active_JJ
        Stat_NNP 3_CD can_MD act_VB synergistically_RB with_IN other_JJ coactivators_NNS to_TO
        stimulate_VB SHRs_NNP transcriptional_NN activity_NN ._. Moreover_RB ,_, while_IN
        Stat_NNP 3_CD did_VBD not_RB affect_VB specificity_NN of_IN AR_NNP to_TO other_JJ steroid_NN
        hormones_NNS rather_RB than_IN androgen_NN ,_, or_CC binding_JJ of_IN AR_NNP to_TO other_JJ
        HREs_NNP ,_, Stat_NNP 3_CD significantly_RB increased_VBD the_DT sensitivity_NN of_IN AR_NNP
        to_TO androgen_NN ._. These_DT results_NNS can_MD add_VB more_RBR light_JJ to_TO the_DT
        mechanism_NN by_IN which_WDT SHRs_NNP ,_, and_CC AR_NNP in_IN particular_JJ ,_, regulate_VB
        gene_NN expression_NN ._.
      
      
        Results_NNS
        
          Effect_NN of_IN Stat_NNP 3_CD on_IN AR-mediated_NNP transcriptional_NN
          activity_NN
          Stat_NNP 3_CD has_VBZ been_VBN shown_VBN to_TO enhance_VB AR-mediated_NNP PSA_NNP
          expression_NN and_CC AR_NNP transcriptional_NN activity_NN in_IN prostate_NN
          cancer_NN cells_NNS [_NN 16_CD 25_CD 28_CD ]_NN ._. We_PRP used_VBD two_CD
          well-characterized_JJ androgen-responsive_JJ luciferase_NN
          reporter_NN plasmids_NNS to_TO study_VB the_DT effect_NN of_IN Stat_NNP 3_CD on_IN
          AR-mediated_NNP transcriptional_NN activity_NN ._. Both_DT reporter_NN
          plasmids_NNS contain_VBP several_JJ AREs_NNP that_WDT are_VBP required_VBN for_IN
          androgen_NN induction_NN ._. As_IN comparison_NN ,_, we_PRP used_VBD a_DT saturating_VBG
          dose_NN ,_, 10_CD nM_NN ,_, of_IN a_DT synthetic_JJ androgen_NN ,_, R_NN 1881_CD ._. CV-_NNP 1_CD cells_NNS
          do_VBP not_RB express_VB endogenous_JJ AR_NNP ,_, therefore_RB ,_, all_DT experiments_NNS
          were_VBD performed_VBN in_IN the_DT presence_NN of_IN ectopic_JJ wild-type_JJ human_JJ
          AR_NNP ._. CV-_NNP 1_CD cells_NNS showed_VBD a_DT strong_JJ response_NN to_TO R_NN 1881_CD compared_VBN
          to_TO vehicle-treated_JJ cells_NNS with_IN both_DT androgen-responsive_JJ
          reporters_NNS used_VBN (_( Fig_NNP ._. 1_LS )_) ._. Cotransfection_NNP of_IN a_DT plasmid_NN
          expressing_VBG a_DT constitutively_RB active_JJ mutant_JJ Stat_NNP 3_CD ,_, Stat_NNP 3_CD C_NNP ,_,
          that_IN forms_NNS homodimers_NNS and_CC translocates_NNS to_TO the_DT nucleus_NN
          without_IN tyrosine_NN phosphorylation_NN ,_, affected_VBD AR_NNP
          transcriptional_NN activity_NN in_IN a_DT dose-response_JJ manner_NN (_( Fig_NNP ._.
          1_LS A_DT )_) but_CC only_RB in_IN the_DT presence_NN of_IN hormone_NN (_( Fig_NNP ._. 1_LS Band_NNP 1_CD C_NNP )_) ._.
          Constitutively_NNP activated_VBN Stat_NNP 3_CD also_RB activates_NNS another_DT
          androgen-responsive_JJ reporter_NN contained_VBD the_DT fragment_NN
          -_: 286_CD /_NN +_NN 28_CD of_IN the_DT rat_NN Probasin_NNP (_( PB_NNP )_) promoter_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ._.
          Wild-type_NNP Stat_NNP 3_CD ,_, that_WDT is_VBZ in_IN a_DT latent_NN cytosolic_JJ state_NN
          without_IN tyrosine_NN phosphorylation_NN nor_CC dimerization_NN ,_, showed_VBD
          no_DT additional_JJ stimulatory_NN effect_NN over_IN the_DT
          androgen-treated_JJ cells_NNS (_( Fig_NNP ._. 1_LS )_)
        
        
          Effect_NN of_IN STAT_NNP 3_CD on_IN transcriptional_NN activity_NN of_IN
          other_JJ SHRs_NNP
          Having_VBG demonstrated_VBN that_IN Stat_NNP 3_CD enhance_VB AR-mediated_NNP
          gene_NN transcription_NN ,_, we_PRP next_RB investigated_VBD the_DT role_NN of_IN
          Stat_NNP 3_CD on_IN transcriptional_NN activation_NN with_IN other_JJ SHRs_NNP ._. For_IN
          GR_NNP and_CC PR_NNP ,_, we_PRP used_VBD the_DT same_JJ reporter_NN plasmid_NN as_IN for_IN AR_NNP ,_,
          ARE-TATA-luciferase_NNP ,_, since_IN it_PRP shows_VBZ promiscuous_JJ response_NN
          to_TO all_DT three_CD SHRs_NNP [_NN 30_CD ]_NN ._. For_IN ER_NNP ,_, we_PRP used_VBD
          ERE-TATA-luciferase_NNP reporter_NN that_WDT is_VBZ specific_JJ for_IN
          estrogen_NN ._. CV-_NNP 1_CD cells_NNS were_VBD also_RB cotransfected_JJ with_IN
          plasmids_NNS expressing_VBG ectopically_RB GR_NNP ,_, PR_NNP or_CC ER_NNP ._. Like_IN the_DT
          AR_NNP ,_, Stat_NNP 3_CD enhances_VBZ all_DT three_CD other_JJ SHRs_NNP tested_VBD in_IN the_DT
          presence_NN of_IN the_DT corresponding_JJ hormone_NN (_( Dex_NNP for_IN GR_NNP ,_, R_NN 5020_CD
          for_IN PR_NNP ,_, or_CC E_NNP 
          2_CD for_IN ER_NNP )_) (_( Fig_NNP ._. 2_LS )_) ._. Taken_VBN together_RB ,_,
          Stat_NNP 3_CD enhances_VBZ four_CD different_JJ SHRs_NNP transcriptional_NN
          activity_NN in_IN the_DT presence_NN of_IN their_PRP$ corresponding_JJ ligand_NN ,_,
          suggesting_VBG that_IN active_JJ Stat_NNP 3_CD acts_NNS as_IN a_DT coactivator_NN for_IN
          nuclear_JJ receptors_NNS ._.
          We_PRP next_JJ compared_VBD the_DT coactivator_NN activity_NN of_IN Stat_NNP 3_CD to_TO
          that_DT of_IN other_JJ known_VBN coactivators_NNS for_IN AR_NNP ._. CV-_NNP 1_CD cells_NNS were_VBD
          transfected_JJ with_IN the_DT same_JJ amount_NN (_( 2_CD μg_NN )_) of_IN plasmid_NN
          expressing_VBG Stat_NNP 3_CD C_NNP ,_, SRC-_NNP 1_CD ,_, CBP_NNP /_NN p_NN 300_CD ,_, TIF-_NNP 2_CD or_CC P_NN /_NN CAF_NNP ,_,
          respectively_RB ._. Cells_NNP transfected_JJ with_IN either_DT coactivator_NN
          or_CC Stat_NNP 3_CD C_NNP showed_VBD comparable_JJ and_CC higher_JJR luciferase_NN
          activity_NN in_IN response_NN to_TO R_NN 1881_CD than_IN cells_NNS treated_VBN with_IN
          hormone_NN alone_RB in_IN the_DT presence_NN of_IN empty_JJ vector_NN (_( Fig_NNP ._. 3_LS )_) ._.
          None_NN of_IN the_DT coactivators_NNS tested_VBN showed_VBD any_DT luciferase_NN
          activity_NN in_IN the_DT absence_NN of_IN hormone_NN (_( data_NNS not_RB shown_VBN )_) ._.
          Stat_NNP 3_CD is_VBZ comparable_JJ to_TO other_JJ coactivators_NNS on_IN AR_NNP
          transcriptional_NN activity_NN :_: SRC-_NNP 1_CD ,_, CBP_NNP /_NN p_NN 300_CD ,_, TIF_NNP 2_CD ,_,
          P_NN /_NN CAF_NNP ._.
          It_PRP has_VBZ been_VBN reported_VBN that_IN coactivators_NNS in_IN combination_NN
          can_MD enhance_VB transcriptional_NN activity_NN of_IN SHRs_NNP compared_VBD to_TO
          when_WRB they_PRP are_VBP delivered_VBN to_TO cells_NNS individually_RB [_NN 29_CD 30_CD ]_NN ._.
          Recently_RB ,_, Giraud_NNP et_CC al_NN [_NN 12_CD ]_NN reported_VBD a_DT direct_JJ
          interaction_NN of_IN Stat_NNP 3_CD with_IN SRC-_NNP 1_CD and_CC CBP_NNP /_NN p_NN 300_CD ._. We_PRP
          determined_VBD whether_IN Stat_NNP 3_CD could_MD act_VB in_IN a_DT
          synergistic_JJ /_NN additive_JJ way_NN when_WRB administered_VBN to_TO cells_NNS
          simultaneously_RB to_TO other_JJ coactivators_NNS ._. As_IN Fig_NNP ._. 3_LS shows_NNS ,_,
          coexpression_NN of_IN active_JJ Stat_NNP 3_CD C_NNP simultaneously_RB to_TO SRC-_NNP 1_CD ,_,
          CBP_NNP /_NN p_NN 300_CD ,_, TIF-_NNP 2_CD or_CC P_NN /_NN CAF_NNP ,_, resulted_VBD in_IN a_DT more_RBR efficient_JJ
          enhancement_NN of_IN the_DT reporter_NN transcription_NN activity_NN driven_VBN
          by_IN AR_NNP as_IN compared_VBN with_IN any_DT of_IN the_DT coactivators_NNS expressed_VBD
          separately_RB ._. A_DT similar_JJ enhancement_NN in_IN luciferase_NN activity_NN
          with_IN simultaneous_JJ delivery_NN of_IN coactivators_NNS was_VBD observed_VBN
          with_IN PR_NNP and_CC ER_NNP (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Stat_NNP 3_CD did_VBD not_RB affect_VB the_DT specificity_NN of_IN AR_NNP for_IN
          non-androgen_JJ steroid_NN hormones_NNS or_CC non-_NN AREs_NNP
          Altered_NNP responses_NNS of_IN AR_NNP include_VBP activation_NN by_IN
          non-androgen_JJ ligands_NNS or_CC recognition_NN of_IN other_JJ hormone_NN
          responsive_JJ elements_NNS different_JJ from_IN AREs_NNP [_NN 22_CD 23_CD ]_NN ._. We_PRP
          studied_VBD if_IN active_JJ Stat_NNP 3_CD could_MD be_VB responsible_JJ for_IN this_DT
          behavior_NN of_IN AR_NNP ._. CV-_NNP 1_CD cells_NNS were_VBD cotransfected_JJ with_IN a_DT
          reporter_NN plasmid_NN responsive_JJ to_TO androgen_NN
          (_( ARE-TATA-luciferase_NNP )_) in_IN the_DT presence_NN or_CC absence_NN of_IN AR_NNP
          and_CC constitutively_RB active_JJ Stat_NNP 3_CD C_NNP (_( Fig_NNP ._. 4_LS top_JJ )_) and_CC cells_NNS
          were_VBD treated_VBN with_IN different_JJ steroid_NN hormones_NNS ._. Stat_NNP 3_CD C_NNP did_VBD
          not_RB alter_VB the_DT specificity_NN of_IN AR_NNP for_IN other_JJ steroid_NN
          hormones_NNS ,_, since_IN it_PRP showed_VBD transcriptional_NN activity_NN only_RB
          in_IN response_NN to_TO androgen_NN but_CC not_RB to_TO Dex_NNP ,_, R_NN 5020_CD or_CC E_NNP 
          2_CD (_( Fig_NNP 4_CD ,_, top_JJ )_) ._.
          To_TO test_VB whether_IN Stat_NNP 3_CD could_MD alter_VB the_DT specificity_NN of_IN
          AR_NNP to_TO other_JJ HREs_NNP ,_, CV-_NNP 1_CD cells_NNS were_VBD cotransfected_JJ with_IN
          reporter_NN plasmids_NNS responsive_JJ to_TO androgen_NN
          (_( ARE-TATA-luciferase_NNP )_) or_CC to_TO estrogen_NN
          (_( ERE-TATA-luciferase_NNP )_) ,_, in_IN the_DT presence_NN or_CC absence_NN of_IN AR_NNP
          and_CC constitutively_RB active_JJ Stat_NNP 3_CD C_NNP (_( Fig_NNP ._. 4_LS bottom_NN )_) ._. With_IN
          ARE-TATA-luciferase_NNP reporter_NN ,_, luciferase_NN activity_NN was_VBD
          dependent_JJ on_IN the_DT presence_NN of_IN AR_NNP and_CC androgen_NN ,_, without_IN any_DT
          effect_NN of_IN Stat_NNP 3_CD C_NNP on_IN the_DT basal_NN levels_NNS of_IN transcription_NN
          (_( Fig_NNP 4_CD ,_, bottom_NN left_VBD )_) ._. Stat_NNP 3_CD C_NNP did_VBD not_RB modify_VB the_DT
          sensitivity_NN of_IN AR_NNP for_IN other_JJ hormone_NN responsive_JJ elements_NNS ,_,
          since_IN there_EX was_VBD no_DT response_NN on_IN the_DT AR_NNP transcriptional_NN
          activity_NN when_WRB we_PRP used_VBD an_DT estrogen-specific_JJ responsive_JJ
          reporter_NN plasmid_NN ,_, ERE-TATA-luciferase_NNP (_( Fig_NNP 4_CD ,_, bottom_JJ
          right_NN )_) ._.
        
        
          Stat_NNP 3_CD does_VBZ not_RB prevent_VB inhibition_NN of_IN AR_NNP by_IN the_DT
          antiandrogen_NN flutamide_NN
          Another_DT altered_VBN response_NN of_IN AR_NNP is_VBZ manifested_JJ in_IN the_DT
          so-called_JJ "_'' flutamide_NN withdrawal_NN syndrome_NN "_'' or_CC more_RBR
          recently_RB broadened_VBD to_TO "_'' antiandrogen_NN withdrawal_NN syndrome_NN "_'' ._.
          In_IN this_DT condition_NN ,_, it_PRP is_VBZ shown_VBN a_DT decrease_NN in_IN serum_NN levels_NNS
          of_IN PSA_NNP after_IN removal_NN of_IN flutamide_NN or_CC other_JJ antiandrogens_NNS
          from_IN the_DT treatment_NN regiment_NN [_NN 33_CD ]_NN ._. We_PRP studied_VBD if_IN active_JJ
          Stat_NNP 3_CD could_MD be_VB involved_VBN in_IN this_DT paradoxical_JJ effect_NN of_IN
          antiandrogens_NNS ._. CV-_NNP 1_CD cells_NNS cotransfected_JJ with_IN an_DT androgen_NN
          responsive_JJ reporter_NN plasmid_NN (_( ARE-TATA-luciferase_NNP )_) ,_, AR_NNP ,_, in_IN
          the_DT presence_NN or_CC absence_NN of_IN constitutively_RB active_JJ Stat_NNP 3_CD C_NNP ,_,
          were_VBD treated_VBN with_IN androgen_NN and_CC flutamide_NN (_( Fig_NNP ._. 5_LS )_) ._. As_IN
          expected_VBN ,_, flutamide_NN blocked_VBN substantially_RB the_DT induction_NN
          of_IN ARE-TATA-luciferase_NNP activity_NN by_IN R_NN 1881_CD in_IN the_DT absence_NN
          of_IN active_JJ Stat_NNP 3_CD C_NNP ._. Similarly_RB ,_, the_DT inhibitory_NN effect_NN of_IN the_DT
          antiandrogen_NN on_IN AR_NNP was_VBD not_RB prevented_VBN by_IN the_DT presence_NN of_IN
          constitutively_RB active_JJ Stat_NNP 3_CD C_NNP ._.
        
        
          Stat_NNP 3_CD affects_VBZ sensitivity_NN of_IN AR_NNP for_IN androgen_NN
          Other_JJ mechanism_NN by_IN which_WDT AR_NNP could_MD show_VB an_DT altered_VBN
          response_NN results_NNS from_IN an_DT increase_NN in_IN its_PRP$ sensitivity_NN to_TO
          very_RB low_JJ levels_NNS of_IN androgen_NN [_NN 22_CD 23_CD ]_NN ._. We_PRP tested_VBD the_DT
          role_NN of_IN active_JJ Stat_NNP 3_CD in_IN this_DT possibility_NN cotransfecting_VBG
          CV-_NNP 1_CD cells_NNS with_IN an_DT androgen_NN responsive_JJ reporter_NN
          (_( ARE-TATA-luciferase_NNP )_) ,_, AR_NNP ,_, in_IN the_DT presence_NN or_CC in_IN the_DT
          absence_NN of_IN constitutively_RB active_JJ Stat_NNP 3_CD C_NNP ._. Cells_NNP were_VBD then_RB
          treated_VBN with_IN different_JJ doses_NNS of_IN androgen_NN ._. Maximal_NNP
          transcriptional_NN activity_NN of_IN AR_NNP was_VBD at_IN 1_CD nM_NN R_NN 1881_CD both_DT in_IN
          the_DT presence_NN and_CC absence_NN of_IN Stat_NNP 3_CD C_NNP (_( Fig_NNP ._. 6_CD )_) ._. Stat_NNP 3_CD C_NNP
          enhanced_JJ luci_NN ferase_NN activity_NN driven_VBN by_IN AR_NNP even_RB at_IN the_DT
          minimal_JJ dose_NN of_IN R_NN 1881_CD tested_VBN ,_, 10_CD pM_NN ,_, which_WDT showed_VBD no_DT
          luciferase_NN activity_NN in_IN the_DT absence_NN of_IN Stat_NNP 3_CD C_NNP ._.
        
      
      
        Discussion_NNP
        Regulation_NNP of_IN gene_NN transcription_NN mediated_JJ by_IN
        hormone-activated_JJ SHRs_NNP involves_VBZ interaction_NN with_IN components_NNS
        of_IN the_DT transcription_NN complex_JJ ._. Coactivators_NNP are_VBP members_NNS of_IN
        the_DT transcription_NN complex_NN ,_, which_WDT act_VBP as_IN bridging_VBG factors_NNS to_TO
        achieve_VB optimal_NN transcription_NN activity_NN ._. Coactivators_NNP are_VBP
        probably_RB present_JJ in_IN the_DT nucleus_NN in_IN preassembled_JJ
        multicomplex_NN units_NNS ready_JJ to_TO associate_JJ to_TO activated_VBN SHRs_NNP ._.
        The_DT role_NN of_IN the_DT coactivators_NNS could_MD be_VB just_RB as_IN bridging_VBG
        factors_NNS ,_, although_IN some_DT of_IN the_DT members_NNS of_IN the_DT p_NN 160_CD family_NN
        and_CC CBP_NNP /_NN p_NN 300_CD present_JJ histone_NN acetyltransferase_NN activity_NN [_NN
        34_CD 35_CD ]_NN ._. Stat_NNP 3_CD is_VBZ a_DT member_NN of_IN the_DT JAK_NNP /_NN STAT_NNP signaling_VBG
        pathway_NN ,_, which_WDT is_VBZ a_DT transcription_NN factor_NN itself_PRP that_IN after_IN
        activation_NN binds_NNS to_TO specific_JJ sequences_NNS in_IN DNA_NNP to_TO regulate_VB
        expression_NN of_IN genes_NNS related_VBN to_TO proliferation_NN ,_,
        differentiation_NN and_CC cell_NN survival_NN ._. Constitutive_NNP activation_NN
        of_IN Stat_NNP 3_CD has_VBZ been_VBN associated_VBN with_IN cell_NN transformation_NN and_CC
        cancer_NN progression_NN ._. Previous_JJ data_NNS including_VBG from_IN our_PRP$ group_NN
        showed_VBD activation_NN of_IN AR_NNP in_IN prostate_NN cancer_NN mediated_JJ by_IN
        activation_NN of_IN Stat_NNP 3_CD [_NN 24_CD 25_CD 26_CD 27_CD 28_CD ]_NN ._.
        Here_RB we_PRP show_VBP that_IN constitutively_RB active_JJ Stat_NNP 3_CD enhances_VBZ
        transcriptional_NN activity_NN of_IN SHRs_NNP ,_, AR_NNP ,_, GR_NNP ,_, PR_NNP ,_, and_CC ER_NNP ,_, in_IN a_DT
        comparable_JJ extent_NN to_TO the_DT stimulation_NN elicit_NN by_IN other_JJ
        coactivators_NNS ,_, and_CC even_RB more_JJR ,_, in_IN a_DT synergistic_JJ manner_NN to_TO
        these_DT other_JJ coactivators_NNS ._. This_DT stimulation_NN is_VBZ independent_JJ
        of_IN the_DT DNA_NNP binding_JJ activity_NN of_IN Stat_NNP 3_CD ,_, since_IN none_NN of_IN the_DT
        luciferase_NN reporters_NNS responsive_JJ to_TO SHRs_NNP used_VBD throughout_IN
        this_DT report_NN contain_VBP the_DT DNA_NNP sequence_NN responsive_JJ to_TO Stat_NNP 3_CD [_NN
        7_CD ]_NN ._. We_PRP cannot_NN rule_NN out_IN ,_, however_RB ,_, that_IN Stat_NNP 3_CD is_VBZ affecting_VBG
        an_DT independent_JJ event_NN that_IN in_IN turn_NN activates_NNS SHR_NNP
        transcriptional_NN activity_NN ._. Nevertheless_RB ,_, direct_JJ
        protein-protein_JJ interaction_NN has_VBZ been_VBN documented_VBN by_IN
        coimmunoprecipitation_NN experiments_NNS between_IN Stat_NNP 3_CD and_CC AR_NNP [_NN 16_CD
        25_CD ]_NN ,_, GR_NNP [_NN 13_CD 14_CD ]_NN ,_, PR_NNP [_NN 36_CD ]_NN ,_, and_CC ER_NNP [_NN 37_CD ]_NN ,_,
        suggesting_VBG that_IN Stat_NNP 3_CD might_MD be_VB involved_VBN directly_RB in_IN
        transcriptional_NN activity_NN elicit_NN by_IN SHRs_NNP ._. Moreover_RB ,_, Stat_NNP 3_CD
        has_VBZ also_RB been_VBN directly_RB associated_VBN with_IN several_JJ
        coactivators_NNS ,_, such_JJ as_IN SRC-_NNP 1_CD and_CC CBP_NNP /_NN p_NN 300_CD [_NN 9_CD 12_CD ]_NN ._.
        Recruitment_NNP of_IN coactivators_NNS to_TO nuclear_JJ receptors_NNS takes_VBZ
        place_NN via_IN a_DT common_JJ motif_NN in_IN the_DT coactivators_NNS containing_VBG a_DT
        core_NN consensus_NN sequence_NN LXXLL_NNP (_( L_NNP ,_, leucine_NN ;_: X_NNP ,_, any_DT
        aminoacid_NN )_) [_NN 38_CD ]_NN ._. Most_JJS of_IN the_DT coactivators_NNS contain_VBP more_JJR
        than_IN one_CD of_IN these_DT motifs_NNS ,_, raising_VBG the_DT question_NN regarding_VBG
        specificity_NN of_IN these_DT motifs_NNS to_TO specific_JJ activating_VBG domains_NNS
        in_IN the_DT nuclear_JJ receptors_NNS ._. Stat_NNP 3_CD also_RB contains_VBZ in_IN its_PRP$
        N-_NNP terminus_JJ one_CD of_IN this_DT motifs_NNS (_( 221_CD LAGLL_NNP 225_CD )_) [_NN 39_CD ]_NN ._.
        Moreover_RB ,_, Stat_NNP 3_CD also_RB presents_VBZ a_DT Ser_NNP at_IN -_: 2_CD position_NN of_IN the_DT
        LXXLL_NNP sequence_NN ,_, which_WDT in_IN the_DT case_NN of_IN the_DT coactivator_NN TRBP_NNP
        defines_VBZ selectivity_NN for_IN nuclear_JJ receptors_NNS [_NN 40_CD ]_NN ._.
        Phosphorylation_NNP of_IN Stat_NNP 3_CD has_VBZ been_VBN reported_VBN to_TO occur_VB only_RB in_IN
        705_CD Tyr_NNP and_CC in_IN 727_NNP Ser_NNP ,_, allowing_VBG dimerization_NN and_CC full_JJ
        transactivating_VBG activity_NN [_NN 41_CD ]_NN ._. Whether_IN this_DT 219_CD Ser_NNP next_JJ
        to_TO the_DT LXXLL_NNP motif_NN is_VBZ involved_VBN in_IN the_DT coactivator_NN activity_NN
        of_IN Stat_NNP 3_CD ,_, and_CC the_DT interaction_NN of_IN Stat_NNP 3_CD with_IN other_JJ
        coactivators_NNS only_RB takes_VBZ place_NN in_IN the_DT context_NN of_IN Stat_NNP 3_CD
        transcription_NN factor_NN activity_NN or_CC also_RB can_MD be_VB part_NN of_IN the_DT
        general_JJ mechanism_NN of_IN the_DT transcription_NN complex_JJ formation_NN
        requires_VBZ further_JJ studies_NNS ._.
        Activation_NNP of_IN AR_NNP is_VBZ a_DT driving_VBG force_NN in_IN development_NN and_CC
        progression_NN of_IN prostate_NN cancer_NN ._. Several_JJ mechanisms_NNS could_MD be_VB
        involved_VBN in_IN this_DT AR_NNP activation_NN [_NN 21_CD 22_CD 23_CD ]_NN ._. Changes_NNS in_IN
        the_DT specificity_NN of_IN AR_NNP broadening_VBG the_DT responsive_JJ spectrum_NN to_TO
        other_JJ steroid_NN hormones_NNS different_JJ to_TO dihydrotestosterone_NN ,_,
        can_MD be_VB caused_VBN by_IN genetic_JJ mutations_NNS affecting_VBG different_JJ
        regions_NNS of_IN AR_NNP ._. We_PRP studied_VBD if_IN active_JJ Stat_NNP 3_CD could_MD be_VB
        sufficient_JJ to_TO alter_VB the_DT specificity_NN of_IN a_DT wild-type_JJ AR_NNP to_TO
        non-steroid_JJ hormones_NNS ._. Our_PRP$ results_NNS indicate_VBP that_IN native_JJ AR_NNP ,_,
        with_IN no_DT mutations_NNS ,_, is_VBZ responsible_JJ only_RB to_TO androgens_NNS ,_, being_VBG
        Stat_NNP 3_CD not_RB sufficient_JJ to_TO alter_VB this_DT feature_NN of_IN AR_NNP ._. Activated_NNP
        Stat_NNP 3_CD d_SYM oes_NNS not_RB affect_VBP the_DT specificity_NN of_IN AR_NNP to_TO bind_NN to_TO
        other_JJ HREs_NNP different_JJ form_NN ARE_VBP ._. Other_JJ altered_VBN response_NN of_IN
        mutated_VBN AR_NNP is_VBZ the_DT paradoxical_JJ agonistic_JJ effect_NN of_IN
        antiandrogens_NNS ._. Also_RB in_IN this_DT case_NN ,_, Stat_NNP 3_CD could_MD not_RB reverse_VB
        the_DT antagonistic_JJ activity_NN of_IN flutamide_NN on_IN a_DT wild-type_JJ AR_NNP ._.
        These_DT results_NNS point_VBP to_TO mutations_NNS in_IN AR_NNP as_IN a_DT necessary_JJ step_NN
        in_IN some_DT of_IN the_DT altered_VBN responses_NNS of_IN AR_NNP seen_VBN in_IN advanced_JJ
        prostate_NN cancer_NN ._.
        Another_DT possible_JJ mechanism_NN by_IN which_WDT a_DT prostate_NN cancer_NN
        circumvents_VBZ the_DT low_JJ levels_NNS of_IN androgens_NNS resulting_VBG from_IN
        androgen_NN ablation_NN therapy_NN is_VBZ by_IN increasing_VBG the_DT sensitivity_NN
        of_IN AR_NNP to_TO very_RB low_JJ levels_NNS of_IN androgens_NNS [_NN 42_CD ]_NN ._. Stat_NNP 3_CD
        increased_VBD the_DT sensitivity_NN of_IN AR_NNP to_TO a_DT dose_NN of_IN androgen_NN that_WDT
        showed_VBD no_DT activity_NN in_IN the_DT absence_NN of_IN Stat_NNP 3_CD ,_, in_IN the_DT absence_NN
        of_IN a_DT mutated_VBN AR_NNP ._. The_DT constitutive_JJ activation_NN of_IN Stat_NNP 3_CD found_VBD
        in_IN prostate_NN cancer_NN [_NN 27_CD 43_CD ]_NN could_MD be_VB an_DT initial_JJ step_NN in_IN
        the_DT clonal_NN selection_NN of_IN malignant_JJ cells_NNS affecting_VBG not_RB only_RB
        Stat_NNP 3_CD -_: regulated_VBN genes_NNS but_CC also_RB AR_NNP ,_, as_IN part_NN of_IN the_DT
        transcription_NN complex_JJ recruited_VBN in_IN response_NN to_TO activated_VBN
        AR_NNP ._. Recently_RB ,_, overexpression_NN of_IN SRC-_NNP 1_CD and_CC TIF-_NNP 2_CD has_VBZ been_VBN
        found_VBN in_IN prostate_NN cancer_NN recurrence_NN after_IN androgen_NN
        deprivation_NN therapy_NN [_NN 44_CD ]_NN ,_, providing_VBG a_DT molecular_JJ basis_NN
        for_IN AR_NNP activation_NN that_WDT could_MD be_VB similar_JJ to_TO the_DT one_CD
        displayed_VBN by_IN Stat_NNP 3_CD in_IN its_PRP$ role_NN as_IN coactivator_NN ._.
        In_IN conclusions_NNS ,_, we_PRP report_VBP here_RB that_IN :_: 1_LS )_) a_DT constitutively_RB
        active_JJ form_NN of_IN Stat_NNP 3_CD stimulates_NNS transcriptional_NN activity_NN of_IN
        SHRs_NNP in_IN a_DT hormone-dependent_JJ manner_NN ;_: 2_LS )_) active_JJ Stat_NNP 3_CD can_MD act_VB
        synergistically_RB with_IN other_JJ c_SYM oactivators_NNS to_TO stimulate_VB SHRs_NNP
        transcriptional_NN activity_NN ;_: 3_LS )_) Stat_NNP 3_CD did_VBD not_RB affect_VB
        specificity_NN of_IN AR_NNP to_TO other_JJ steroid_NN hormones_NNS different_JJ than_IN
        androgen_NN ,_, or_CC binding_JJ of_IN AR_NNP to_TO other_JJ HREs_NNP ;_: 4_LS )_) Stat_NNP 3_CD
        increases_NNS the_DT sensitivity_NN of_IN AR_NNP to_TO androgen_NN ._. These_DT results_NNS
        can_MD help_VB to_TO elucidate_NN the_DT mechanism_NN by_IN which_WDT SHRs_NNP in_IN
        general_JJ ,_, and_CC AR_NNP in_IN particular_JJ ,_, regulate_VB gene_NN
        expression_NN ._.
      
      
        Methods_NNP
        
          Plasmids_NNP
          Luciferase_NNP reporter_NN plasmids_NNS containing_VBG specific_JJ
          responsive_JJ elements_NNS for_IN AR_NNP ,_, GR_NNP ,_, and_CC PR_NNP
          (_( GRE-TATA-luciferase_NNP )_) and_CC ER_NNP (_( ERE-TATA-luciferase_NNP )_) have_VBP
          been_VBN described_VBN elsewhere_RB [_NN 29_CD 30_CD ]_NN ;_: another_DT
          androgen-responsive_JJ reporter_NN contained_VBD the_DT fragment_NN
          -_: 286_CD /_NN +_NN 28_CD of_IN the_DT rat_NN Probasin_NNP (_( PB_NNP )_) promoter_NN ,_, and_CC was_VBD
          obtained_VBN from_IN Dr_NNP ._. R_NN ._. Matusik_NNP ,_, Vanderbilt_NNP University_NNP ,_, TN_NNP [_NN
          31_CD ]_NN ._. An_DT expression_NN plasmid_NN for_IN wild-type_JJ hAR_NN was_VBD kindly_RB
          provided_VBN by_IN Dr_NNP ._. C_NNP ._. Chang_NNP ,_, University_NNP of_IN Rochester_NNP ,_, NY_NNP ._.
          Expression_NNP plasmids_NNS for_IN hGR_NN ,_, hPR_NN α_NN and_CC ER_NNP have_VBP been_VBN also_RB
          described_VBN [_NN 29_CD 30_CD ]_NN ._. Wild-type_NNP inactive_JJ form_NN of_IN Stat_NNP 3_CD
          (_( pCAGGS-HA-Stat_JJ 3_LS )_) was_VBD from_IN Dr_NNP ._. T_NN ._. Hirano_NNP ,_, Osaka_NNP
          University_NNP ,_, Japan_NNP [_NN 32_CD ]_NN ._. The_DT plasmid_NN expressing_VBG a_DT
          constitutively_RB active_JJ form_NN of_IN Stat_NNP 3_CD (_( Stat_NNP 3_CD C-F_NNP lag_NN )_) was_VBD
          obtained_VBN from_IN Dr_NNP ._. J_NNP ._. Darnell_NNP ,_, jr_NN ._. [_NN 18_CD ]_NN ._. This_DT
          constitutively_RB activated_VBN Stat_NNP 3_CD (_( a_DT mutant_JJ produced_VBN by_IN
          substitution_NN of_IN the_DT cysteine_NN residues_NNS within_IN the_DT
          COOH-terminal_NNP loop_NN of_IN the_DT SH_NNP 2_CD domain_NN of_IN Stat_NNP 3_LS )_) induces_VBZ
          cellular_JJ transformation_NN and_CC tumor_NN formation_NN in_IN nude_JJ mice_NNS
          [_NN 18_CD ]_NN ._. The_DT plasmids_NNS to_TO express_VB other_JJ coactivators_NNS
          (_( SRC-_NNP 1_CD ,_, CBP_NNP /_NN p_NN 300_CD ,_, TIF_NNP 2_CD and_CC PCAF_NNP )_) have_VBP been_VBN described_VBN
          elsewhere_RB [_NN 29_CD 30_CD ]_NN ._.
        
        
          Cells_NNP and_CC transfections_NNS
          CV-_NNP 1_CD cells_NNS were_VBD maintained_VBN in_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN
          (_( Bio-_NNP Whittaker_NNP ,_, Walkersville_NNP ,_, MD_NNP )_) ,_, 100_CD u_NN /_NN ml_NN penicillin_NN ,_,
          100_CD μg_NN /_NN ml_NN streptomycin_NN in_IN DMEM_NNP ._. Twenty_CD four_CD hours_NNS before_IN
          transfection_NN ,_, cells_NNS were_VBD plated_JJ in_IN 12_CD well_RB plates_NNS (_( 1_CD ._. 2_LS ×_NN
          105_CD per_IN well_RB )_) in_IN 5_CD %_NN charcoal_NN stripped_VBD serum_NN (_( Hyclone_NNP ,_,
          Logan_NNP ,_, UT_NNP )_) ,_, antibiotics_NNS ,_, and_CC 2_CD mM_NN L-_NNP glutamine_NN in_IN phenol_NN
          red-free_JJ DMEM_NNP ._. For_IN transfections_NNS ,_, we_PRP used_VBD (_( per_IN well_RB )_) 0_CD ._. 2_CD
          μg_NN reporter_NN ,_, 0_CD ._. 2_CD μg_NN receptor_NN ,_, and_CC 2_CD μg_NN coactivator_NN or_CC
          empty_JJ vector_NN ._. In_IN experiments_NNS studying_VBG synergy_NN of_IN
          coactivators_NNS ,_, the_DT total_JJ amount_NN of_IN DNA_NNP was_VBD kept_VBN constant_JJ
          at_IN 4_CD ._. 4_CD μg_NN per_IN well_RB ._. Transfections_NNP were_VBD performed_VBN with_IN
          Superfect_NNP reagent_NN according_VBG to_TO the_DT manufacturer_NN 's_POS
          protocol_NN (_( Qiagen_NNP ,_, Valencia_NNP ,_, CA_NNP )_) ._. Three_CD hours_NNS after_IN
          transfection_NN ,_, medium_NN was_VBD removed_VBN and_CC hormones_NNS added_VBD in_IN
          phenol_NN red-free_JJ DMEM_NNP containing_VBG 5_CD %_NN charcoal_NN stripped_VBD
          serum_NN and_CC antibiotics_NNS ._. Dihydrotestosterone_NNP (_( DHT_NNP )_) ,_,
          dexamethasone_NN (_( Dex_NNP )_) ,_, estradiol_NN (_( E_NNP 
          2_LS )_) ,_, and_CC the_DT synthetic_JJ anti-androgen_JJ
          flutamide_NN were_VBD from_IN Sigma_NNP (_( Saint_NNP Louis_NNP ,_, MO_NNP )_) ._. The_DT
          synthetic_JJ analogs_NNS of_IN androgen_NN and_CC progesterone_NN ,_, R_NN 1881_CD and_CC
          R_NN 5020_CD ,_, respectively_RB ,_, were_VBD from_IN New_NNP England_NNP Nuclear_NNP
          (_( Boston_NNP ,_, MA_NNP )_) ._.
        
        
          Luciferase_NNP activity_NN
          Thirty_NNP six_CD hours_NNS after_IN incubation_NN with_IN hormones_NNS ,_,
          luciferase_NN activity_NN was_VBD determined_VBN in_IN cell_NN extracts_NNS
          according_VBG to_TO manufacturer_NN 's_POS suggestions_NNS (_( Promega_NNP ,_,
          Madison_NNP ,_, WI_NNP )_) ._. Luciferase_NNP activity_NN was_VBD normalized_JJ per_IN μg_NN
          protein_NN ,_, determined_VBN by_IN Bradford_NNP assay_NN (_( Coomasie_NNP Plus_NNP ,_,
          Pierce_NNP ,_, Rockford_NNP ,_, IL_NNP )_) ._. Data_NNP are_VBP presented_VBN as_IN a_DT
          representative_NN experiment_NN ,_, which_WDT was_VBD independently_RB
          repeated_VBN at_IN least_JJS three_CD times_NNS ._.
        
      
      
        Authors_NNP '_'' Contributions_NNP
        DeMiguel_NNP and_CC Lee_NNP carried_VBD out_RP the_DT entire_JJ experiments_NNS ._.
        Onate_NNP and_CC Gao_NNP conceived_VBD of_IN the_DT study_NN ,_, and_CC participated_VBD in_IN
        its_PRP$ design_NN and_CC coordination_NN ._.
      
    
  
